Bellerophon Therapeutics Stock Revenue
| BLPHDelisted Stock | USD 0.71 0.01 1.43% |
Bellerophon Therapeutics fundamentals help investors to digest information that contributes to Bellerophon Therapeutics' financial success or failures. It also enables traders to predict the movement of Bellerophon Pink Sheet. The fundamental analysis module provides a way to measure Bellerophon Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bellerophon Therapeutics pink sheet.
Bellerophon |
Bellerophon Therapeutics Company Revenue Analysis
Bellerophon Therapeutics' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
CompetitionBased on the latest financial disclosure, Bellerophon Therapeutics reported 0.0 of revenue. This is 100.0% lower than that of the Health Care Equipment & Supplies sector and 100.0% lower than that of the Health Care industry. The revenue for all United States stocks is 100.0% higher than that of the company.
Bellerophon Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bellerophon Therapeutics' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Bellerophon Therapeutics could also be used in its relative valuation, which is a method of valuing Bellerophon Therapeutics by comparing valuation metrics of similar companies.Bellerophon Therapeutics is currently under evaluation in revenue category among its peers.
Bellerophon Fundamentals
| Return On Equity | -1.39 | ||||
| Return On Asset | -0.6 | ||||
| Profit Margin | (2.20) % | ||||
| Operating Margin | (2.48) % | ||||
| Current Valuation | (9.32 M) | ||||
| Shares Outstanding | 12.23 M | ||||
| Shares Owned By Insiders | 3.97 % | ||||
| Shares Owned By Institutions | 45.08 % | ||||
| Number Of Shares Shorted | 90.45 K | ||||
| Price To Earning | 5.33 X | ||||
| Price To Book | 1.05 X | ||||
| EBITDA | (22.39 M) | ||||
| Net Income | (19.83 M) | ||||
| Cash And Equivalents | 16.33 M | ||||
| Cash Per Share | 1.71 X | ||||
| Total Debt | 203 K | ||||
| Debt To Equity | 0.05 % | ||||
| Current Ratio | 3.12 X | ||||
| Book Value Per Share | 0.46 X | ||||
| Cash Flow From Operations | (17.77 M) | ||||
| Short Ratio | 1.26 X | ||||
| Earnings Per Share | (0.34) X | ||||
| Target Price | 2.0 | ||||
| Number Of Employees | 18 | ||||
| Beta | 0.55 | ||||
| Market Capitalization | 1.25 M | ||||
| Total Asset | 7.93 M | ||||
| Retained Earnings | (252.08 M) | ||||
| Working Capital | 2.16 M | ||||
| Current Asset | 29.45 M | ||||
| Current Liabilities | 8.07 M | ||||
| Z Score | -49.75 | ||||
| Net Asset | 7.93 M |
About Bellerophon Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bellerophon Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bellerophon Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bellerophon Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Other Consideration for investing in Bellerophon Pink Sheet
If you are still planning to invest in Bellerophon Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Bellerophon Therapeutics' history and understand the potential risks before investing.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |